BridgeBio Pharma (BBIO) Goodwill & Intangibles (2018 - 2026)

BridgeBio Pharma's Goodwill & Intangibles history runs 8 years deep, the most recent figure standing at $27.4 million for Q1 2026.

• In Q1 2026, Goodwill & Intangibles fell 1.59% year-over-year to $27.4 million; the TTM figure through Mar 2026 stood at $27.4 million (down 1.59% YoY), while the FY2025 annual figure was $28.1 million, up 17.35% from the prior year.
• Goodwill & Intangibles came in at $27.4 million for Q1 2026 at BridgeBio Pharma, down from $28.1 million in the prior quarter.
• In the past five years, Goodwill & Intangibles ranged from a high of $30.5 million in Q1 2022 to a low of $23.9 million in Q4 2024.
• A 5-year average of $27.5 million and a median of $27.8 million in 2025 frame the typical range for Goodwill & Intangibles.
• On a YoY basis, Goodwill & Intangibles climbed as much as 91.41% in 2022 and fell as far as 36.56% in 2022.
• BridgeBio Pharma's Goodwill & Intangibles stood at $28.7 million in 2022, then retreated by 8.33% to $26.3 million in 2023, then declined by 9.09% to $23.9 million in 2024, then climbed by 17.35% to $28.1 million in 2025, then retreated by 2.56% to $27.4 million in 2026.
• According to Business Quant data, Goodwill & Intangibles over the past three periods registered $27.4 million, $28.1 million, and $28.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison